Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from ChromaDex

Top 3 Accelerating Chemical Stocks to Consider

The chemical industry is well-positioned for significant long-term growth thanks to sustained demand across diverse sectors, a shift toward sustainability and green chemistry, and rapid digital transformation. So, it could be wise to invest in top chemical stocks NewMarket (NEU), Mitsubishi Chemical Group (MTLHY), and ChromaDex (CDXC) for substantial gains.…

StockNews.com · Feb 6, 2024

ChromaDex (CDXC) vs. Micromidas (ORGN): What's the Better Chemical Stock Under $5?

The chemical industry is well-poised for robust growth in the long term, thanks to the strong demand for specialty chemicals and the integration of digital technologies to drive value chain improvements and sustainability; and develop innovative products. Chemical producers ChromaDex (CDXC) and Origin Materials (ORGN) should benefit from the industry…

StockNews.com · Jun 1, 2023

$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones jumped by more than 750 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall…

Benzinga · Oct 4, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Benzinga's Top Ratings Upgrades, Downgrades For August 16, 2022

Benzinga · Aug 16, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 11, 2022

Benzinga · Aug 11, 2022

4 Analysts Have This to Say About ChromaDex

ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings within the last quarter:

Benzinga · Jun 7, 2022

ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China

ChromaDex Corp (NASDAQ:CDXC) has agreed to establish a joint venture through its wholly-owned subsidiary ChromaDex Asia Limited. ChromaDex Asia is expected to assume the distribution agreement with Sinopharm Xingsha relating to the commercialization of Tru Niagen in mainland China and its territories, excluding Hong Kong, Macau, and Taiwan. Also See: ChromaDex Shares Gain On Niagen Supply Pact With…

Benzinga · May 20, 2022

Read news from The Economist, FT, and more,
with one subscription

Where ChromaDex Stands With Analysts

Within the last quarter, ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings:

Benzinga · May 13, 2022

Recap: ChromaDex Q1 Earnings

ChromaDex (NASDAQ:CDXC) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex missed estimated earnings by 22.22%, reporting an EPS of $-0.11 versus an estimate of $-0.09.

Benzinga · May 12, 2022

Recap: ChromaDex Q4 Earnings

ChromaDex (NASDAQ:CDXC) reported its Q4 earnings results on Wednesday, March 9, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex beat estimated earnings by 20.0%, reporting an EPS of $-0.08 versus an estimate of $-0.1.

Benzinga · Mar 9, 2022

ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements

ChromaDex Corp (NASDAQ: CDXC) has

Benzinga · Jan 20, 2022

Coverage From

People

Mangeet Kaur BounsMangeet

595 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.